Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

Overview of attention for article published in Frontiers in oncology, July 2024

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 6,544 followers.

New Research: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma https://t.co/RrDseBhjkO #FrontiersIn #Oncology

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.